Trial Information
Ofatumumab in Relapsed Nodular Lymphocyte Predominant Hodgkin Lymphoma (NLPHL)
Inclusion Criteria:
- relapsed nodular lymphocyte predominant hodgkin lymphoma
- age 18 - 75
- review of diagnosis by experienced pathologist
- no major organ dysfunction
Exclusion Criteria:
- classical hodgkin lymphoma
- CD20 antibody treatment within the last 6 months prior enrollment
- chronic or current infectious disease requirering systemic antibiotics
- other past or current malignancy
Type of Study:
Interventional
Study Design:
Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Outcome Measure:
Overall response rate
Outcome Time Frame:
12 months after end of treatment
Safety Issue:
No
Principal Investigator
Andreas Engert, MD
Investigator Role:
Principal Investigator
Investigator Affiliation:
University of Cologne
Authority:
Germany: Paul-Ehrlich-Institut
Study ID:
Uni-Koeln-1432
NCT ID:
NCT01187303
Start Date:
May 2011
Completion Date:
Related Keywords:
- Relapsed NLPHL
- Hodgkin Disease
- Lymphoma
